RACC surges on merger agreement with Oak Hill Bio for Phase 3 Angelman asset
RACC surges 20% on merger agreement with Oak Hill Bio for Phase 3 Angelman asset
- RACC announced business combination with OHB Pediatrics (Oak Hill Bio) on July 27 2026
- Oak Hill Bio develops rugonersen antisense oligonucleotide in pivotal Phase 3 BEACON trial
- Transaction values Oak Hill at $160M base equity with ~$175M gross proceeds expected
- Proceeds include fully backstopped $75M trust RA Capital commitment plus $55M PIPE
- Combined company to trade on Nasdaq as OAKH after H2 2026 close subject to approvals
- News drove immediate volume and price spike to around $13 per share intraday
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.